BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
A. Goncalves
Honoraria - Bayer
F. Viret
No relevant relationships to disclose
E. François
No relevant relationships to disclose
L. Dahan
No relevant relationships to disclose
H. Perrier
No relevant relationships to disclose
R. Lamy
No relevant relationships to disclose
D. Re
No relevant relationships to disclose
R. Largillier
No relevant relationships to disclose
M. Gasmi
No relevant relationships to disclose
X. Tchiknavorian
No relevant relationships to disclose
O. Turrini
No relevant relationships to disclose
L. Moureau-Zabotto
No relevant relationships to disclose
J. Delpero
No relevant relationships to disclose
P. Viens
No relevant relationships to disclose